McAdam LLC’s Quest Diagnostics DGX Stock Holding History

McAdam LLC’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2	Closed	–	–	182
2018 Q3	$0	Hold	2	–	–	﹤0.01%	675
2018 Q2	$0	Hold	2	–	–	﹤0.01%	675
2018 Q1	$0	Buy	+2	New	+$205	﹤0.01%	770

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

McAdam LLC's DGX Position: Q4 2018 in Review

McAdam LLC sold out of Quest Diagnostics (DGX) in Q4 2018, closing a stake of 2 shares.

McAdam LLC first reported a position in DGX in Q1 2018 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 624 funds tracked by Wall St. Rank hold DGX as of Q4 2018.

McAdam LLC reported no remaining Quest Diagnostics position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 2 Quest Diagnostics shares in Q4 2018.
McAdam LLC first reported a position in Quest Diagnostics in Q1 2018 and held it in 3 quarters.
McAdam LLC's Quest Diagnostics position peaked at $0 in Q3 2018.
624 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.